Filter posts

“Diverse Candidates Can Win If They Can Get the Interview.”

Diversity is gaining more attention among biotech investors and companies alike. At entry level, 50% …

#BIF17: Looking Ahead to 2018 Policy Landscape

The past year has seen a number of important changes in the legislative and policy …

A Discussion on Value at #BIF17

In a recent op-ed, BIO President and CEO Jim Greenwood wrote about a promising trend …

“Invest in What’s Cool. Invest in Science that Matters.”

One reality of the biotech industry that’s often overlooked is that 90% of biotech companies …

#BIF17: Turning the Tide on Antimicrobial Resistance

It’s no secret that antimicrobial resistance (AMR) is one of the most serious public health …

Challenges and Opportunities in Personalized Medicine

Last week the sixth annual Patient and Health Advocacy Summit brought hundreds of patient advocates, …

Patient and Industry Collaboration: Key to Successful Clinical Trials?

During the BIO Patient & Health Advocacy Summit last week, a panel led by Julie …

Welcome to the 2017 BIO Patient and Health Advocacy Summit!

Patients are at the forefront of everything we do. Each year BIO brings the patient …

Partnering is Key to Success at 2017 BIO Investor Forum

The 2017 BIO Investor Forum is less than a month away, and BIO’s One-on-One Partnering™ …

Exploring the Richness of Companies and Investors at the BIO Investor Forum

The 16th Annual BIO Investor Forum, taking place October 17th-18th in San Francisco, is the …